Immunology Investor Event

sanofi Address airway inflammation to improve lung function and reduce exacerbations in COPD Potential treatment paradigm Active Smoker High Blood eos DupixentⓇ Paula 67 yr woman COPD for 10 years 3 exacerbations in last year Frequent SOB, Cough Meds: ICS/LABA/LAMA DupixentⓇ High Blood eos itepekimab Former Smoker Low Blood eos itepekimab Itepekimab is under investigation and not yet approved by any regulatory agency. DupixentⓇ is under investigation in COPD and not yet approved by any regulatory agency to treat COPD. 39 Immunology Investor Event

View entire presentation